Results 111 to 120 of about 7,679 (193)

Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma? Mepolizumab: Hangi durum daha fazla fayda sağlar: Burun polipleri mi, eozinofilik astım mı? [PDF]

Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma? Introduction: The negative effects of eosinophilic severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) on quality of life are well known.
PAÇACI ÇETİN, GÜLDEN, YILMAZ, İNSU, AÇAR, ELİF, AKTAŞ YAPICI, ELİF, TÜRK, MURAT, ARSLAN, BAHAR, BOZKURT YILMAZ, HATİCE EYLÜL, ŞEKER, SERHAT, KÖYLÜCE, SERPİL   +8 more
core   +1 more source

Cost-effectiveness of mepolizumab for severe eosinophilic asthma in China [PDF]

To evaluate the economic value of mepolizumab as an add-on therapy to the standard of care (SoC) for patients with severe eosinophilic asthma in China.
Wang Zhen (4615225), Li Ying (136738), Ma Wenbin (11934811), Xiong Chaogang (18144183), Zhao Yuan (547890), Lei Qian (292302), Gu Xin (17475110), Zhang Shengjie (18144189), Feng Weiyi (18144192), An Mengna (18144186), Zhang Xin (6264812)   +10 more
core   +1 more source

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis [PDF]

International audienceBACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an
Jison, Maria, Wechsler, Michael M.E., Jayne, David, Jackson, David J., Shavit, Anat, Walz, Bastian, Wechsler, Michael E., Merkel, Peter PA, Jackson, David J, Mccrae, Christopher, Jackson, David, Nair, Parameswaran, Börjesson Sjö, Lena, Jayne, David R.W., Jayne, David R.W.David, Fan, Ying, Wechsler, Michael, Roufosse, Florence, Merkel, Peter, Merkel, Peter A., Walton, Claire, Bourdin, Arnaud, Sjö, Lena Börjesson, Necander, Sofia, Fan, Yingying, Terrier, Benjamin   +25 more
core   +1 more source

Mepolizumab [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Mepolizumab for the management of chronic rhinosinusitis with nasal polyps across the United States: A retrospective study

Journal of Allergy and Clinical Immunology: Global
Background: Retrospective data are limited on the effectiveness of mepolizumab treatment that is reflective of real-world practice in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Juan Carlos Cardet, MD, MPH, Jared Silver, MD, Martin Maldonado-Puebla, MD, François Laliberté, MA, Chi Gao, PhD, Ramya Ramasubramanian, PhD, Annalise Hilts, BA, Kaixin Zhang, MSc, Jeremiah Hwee, PhD, Waseem Ahmed, MBA, Amy G. Edgecomb, PharmD, MPH   +10 more
doaj   +1 more source

Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma

Journal of Asthma and Allergy, 2020
Jared Silver,1 Michael Bogart,1 Elizabeth Packnett,2 Juan Wu,2 Donna McMorrow,2 Beth Hahn1 1US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2Life Sciences, IBM Watson Health, Bethesda, MD, USACorrespondence: Beth Hahn Email beth.a.hahn@gsk ...
Silver J, Bogart M, Packnett E, Wu J, McMorrow D, Hahn B   +5 more
doaj  

Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases

Lung India
The Interleukin-5 (IL-5)-mediated pathogenic role of eosinophils in airway disorders including severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and rare hyper ...
Dipti Gothi, Raghupathi Narasimhan, Randeep Guleria, Manu Chopra, Aanchal Gvalani, Rashmi Hegde   +5 more
doaj   +1 more source

A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT)

Therapeutic Advances in Respiratory Disease
Background: REMIT is the first real-world study of mepolizumab effectiveness in patients with severe asthma (SA) in Taiwan. Objectives: The primary objective evaluated changes in clinically significant exacerbations (CSEs; defined as use of oral ...
Shih-Lung Cheng, Shu-Min Lin, Chung-Kan Peng, Ming-Cheng Chan, Sheng-Yeh Shen, Ping-Hung Kuo, Chien-Hao Lai, Chou-Chin Lan, Chung-Yu Chen, Ching-Hsiung Lin, Kuang-Ming Liao, Po-Hao Feng, Jiin-Torng Wu, Yu-Feng Wei, Xiaomeng Xu, Rafael Alfonso-Cristancho, Tina Lai, Aldo Navarro, Dominique Milea, Diahn-Warng Perng   +19 more
doaj   +1 more source

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases [PDF]

, 2015
Francesco Menzella,1 Mirco Lusuardi,2 Carla Galeone,1 Sofia Taddei,1 Luigi Zucchi1 1Department of Cardiac-Thoracic-Vascular and Intensive Care Medicine, Pneumology Unit, Istituto di Ricovero e Cura a Carattere Scientifico- Arcispedale Santa Maria Nuova ...
Galeone C, Taddei S, Menzella F, Lusuardi M, Zucchi L   +4 more
core  

Biologic Switching in Patients with Severe Asthma: Effects on Exacerbations, Corticosteroid Use and Lung Function. [PDF]

J Clin Med
Dindar Çelik F, Aksu K.
europepmc   +1 more source